Item Type | Name |
Concept
|
Burkitt Lymphoma
|
Concept
|
Lymphoma, Large B-Cell, Diffuse
|
Concept
|
Lymphoma, Non-Hodgkin
|
Concept
|
Lymphoma, B-Cell
|
Concept
|
Lymphoma, Mantle-Cell
|
Concept
|
Lymphoma, Follicular
|
Concept
|
Lymphoma
|
Concept
|
Lymphoma, B-Cell, Marginal Zone
|
Academic Article
|
The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma.
|
Academic Article
|
Autologous stem cell transplantation following induction therapy with an anthracycline-based regimen including interferon-alpha for low-grade non-Hodgkin's lymphoma.
|
Academic Article
|
Posttransplant lymphoproliferative disorder: extranodal marginal zone lymphoma occurring after renal transplantation.
|
Academic Article
|
Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
|
Academic Article
|
Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
|
Academic Article
|
Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma.
|
Academic Article
|
Relapsed non-Hodgkin lymphoma in fraternal twins managed successfully with rituximab maintenance therapy.
|
Academic Article
|
Durable remission of intravascular lymphoma with central nervous system involvement following chemotherapy and rituximab.
|
Academic Article
|
GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas.
|
Academic Article
|
Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients.
|
Academic Article
|
Long-term remission of paroxysmal nocturnal hemoglobinuria following chemoimmunotherapy for non-Hodgkin lymphoma.
|
Academic Article
|
Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemia.
|
Academic Article
|
Bendamustine and Rituximab: Complete Response in a 62-Year-Old Female with an Aggressive Lymphoma and an Ejection Fraction of 20.
|
Academic Article
|
Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma.
|
Academic Article
|
Impact of cachexia on outcomes in aggressive lymphomas.
|
Academic Article
|
Breast implant-associated anaplastic large-cell lymphoma and the role of brentuximab vedotin (SGN-35) therapy: A case report and review of the literature.
|
Academic Article
|
Phase 2 study of CHOP-R-14 followed by 90Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphoma.
|
Academic Article
|
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
|
Academic Article
|
Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells.
|
Academic Article
|
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.
|
Academic Article
|
Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma.
|
Academic Article
|
When Monoclonal Gammopathy is of Renal Significance: A Case Study of Crystalglobulinemia From Chicago Multiple Myeloma Rounds.
|
Academic Article
|
Orbital Mucosa-Associated Lymphoid Tissue Lymphoma and Primary Cutaneous Classical Hodgkin Lymphoma: A Rare Case Report and Review of the Literature.
|
Academic Article
|
Significance of isolated deletion (20q) in donor cells after allogeneic hematopoietic cell transplantation.
|
Academic Article
|
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers.
|
Academic Article
|
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study.
|
Academic Article
|
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis.
|
Academic Article
|
EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort.
|
Academic Article
|
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers.
|
Academic Article
|
Parsaclisib, a PI3Kd inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study.
|